PWM
ITCI

Perigon Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Perigon Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,000
Closed -$651K – 279
2018
Q3 		$651K Hold
30,000
– – 0.16% 107
2018
Q2 		$530K Sell
30,000
-5,955
-17% -$121K 0.16% 120
2018
Q1 		$757K Hold
35,955
– – 0.28% 69
2017
Q4 		$521K Hold
35,955
– – 0.19% 74
2017
Q3 		$567K Buy
+35,955
New +$528K 0.18% 103

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perigon Wealth Management's ITCI Position: Q4 2018 in Review

Perigon Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2018, closing a stake of 30,000 shares — an estimated $651K sold.

Perigon Wealth Management first reported a position in ITCI in Q3 2017 and held it in 5 quarters. The position peaked at $757K in Q1 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q4 2018.

  • Perigon Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 30,000 Intra-Cellular Therapies Inc. shares in Q4 2018, an estimated $651K.
  • Perigon Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 5 quarters.
  • Perigon Wealth Management's Intra-Cellular Therapies Inc. position peaked at $757K in Q1 2018.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2018.

Based on Perigon Wealth Management's 13F filing for Q4 2018, filed 11 Feb 2019.